Oncotarget releases new study on therapeutic treatment for breast cancer patients

Aggressive breast cancer study shows that a more therapeutic treatment could be in the future for those who have the hormone “ERB” (Estrogen Receptor Bata). Oncotarget has also published an article that is targeting specific molecules for further research. These molecules could provide better medications for those with breast cancer. Those that have been diagnosed with “TNBC” (Triple Negative Breast Cancer) are also considered Aggressive types. 15 percent of those diagnosed cancer types lose the proteins that bind the hormones estrogen and progesterone that is present in normal breast cells. The lose of these receptors makes cancers more resistant to common treatments. Learn more about Oncotarget at Research Gate.

Considering all the new advancements in treatment methods TBNC patients are not properly diagnosed since the cancer is likely to spread to other organs. Researchers are working on understanding the characteristics of the cells and molecular pathways to identify the best treatment options. The research involving introducing estrogen to cancer cells could show a reduction of the cancer tumors or prevent their growth. These finding will be further evaluated before they are considered for clinical trial.

Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex

Oncotarget recently awarded four biomedical researchers grants to attend a cancer science conference in Singapore. The four researchers were committed to discussing the advancements in cancer science.

At the (Frontiers in Cancer Science 2017) scientists from around the world gathered to discuss recent findings in cancer research. Oncotarget was not only proud to provide that opportunity to the researchers. Oncotarget is for the pursuit, maximization and the circulation of science discovery information. Follow Oncotarget journal on Twitter.

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science

Eric Lefkofksy Revolutionizing Cancer Treatment with Tempus

Eric Lefkofsky is a serial entrepreneur best known for his involvement in companies such as Groupon and Tempus. (https://www.linkedin.com/in/ericlefkofsky) Lefkofsky was raised in Southfield, Michigan and attended Southfield-Lathrup High School. He furthered his education at the University of Michigan where he graduated with honors. In 1993, Lefkofsky earned his Juris Doctor from the University of Michigan Law School. While still in attendance at the University of Michigan, Lefkofsky began selling carpet to earn money on the side.

Throughout his entrepreneurial career, Lefkofsky has started many projects with his college friend Brad Keywell. Their first business endeavor was established in 1993 when the duo purchased the Brandon Apparel clothing line in Madison, Wisconsin. Separate from Keywell, Lefkofsky co-founded InnerWorkings in 2001. The business focused on print services for smaller companies and grew rapidly within its first year. InnerWorkings entered into the stock market and was publicly traded in 2006.

Lefkofsky continued to found several successful companies throughout his career. In 2007, he started his most successful project to date. ThePoint.com started out as an e-Commerce website that eventually grew into the world-renowned Groupon company. Over the next few years, countless investors would provide millions of dollars in funding to Lefkofsky’s company. In fact, Forbes declared Groupon as the fastest growing company in history.

The Tempus technology company has been Lefkofsky’s most recent endeavor. He co-founded the company in 2016 in an effort to revolutionize the way cancer is treated. Tempus utilizes data-driven technology and analysis to give doctors a more specialized approach to cancer treatment. With proprietary technology and unique methods, Tempus is able to provide doctors with a deeper understanding of each patient’s cancer. Doctors and other health-care providers are then able to customize treatments for each individual. This specialization makes for more effective treatments overall.

As a resident of Chicago, Lefkofsky has always been very active within his community. He serves on the board of directors for the Children’s Memorial Hospital, The Museum of Science and Industry and The Art Institute of Chicago. Lefkofsky also serves as co-chairman for the Technology Council of World Business Chicago. In 2008, he also joined the committee petitioning to bring the 2016 Summer Olympics to Chicago. The historical Steppenwolf Theatre Company appointed Lefkofsky as a Trustee member as well.

Along with his business ventures, Eric Lefkofsky is also very active philanthropically. The Lefkofsky Foundation was founded by Eric and his wife, Elizabeth. Through this foundation, the couple works with different organizations and charities to give back to the community both locally and globally. Since its creation in 2006, the Lefkofsky Foundation has worked with over 50 different organizations. Eric and Elizabeth Lefkofsky support efforts around the world with focuses on education, science and charitable work.

More information about Eric Lefkofsky:

www.forbes.com/profile/eric-lefkofsky